Health Care [ 11/12 ] | Pharmaceuticals [ 66/74 ]
NASDAQ | Common Stock
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.
The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.37 Decreased by -2.78% | -0.34 Decreased by -8.82% |
| May 13, 24 | -0.54 Decreased by -200.00% | -0.32 Decreased by -68.75% |
| Mar 13, 24 | -0.42 Decreased by -366.67% | -0.24 Decreased by -75.00% |
| Nov 7, 23 | -0.24 Decreased by -71.43% | -0.21 Decreased by -14.29% |
| Aug 10, 23 | -0.36 Decreased by -140.00% | -0.16 Decreased by -125.00% |
| May 4, 23 | -0.18 Increased by +40.00% | -0.16 Decreased by -12.50% |
| Mar 16, 23 | -0.09 Increased by +60.87% | -0.15 Increased by +40.00% |
| Nov 8, 22 | -0.14 Increased by 0.00% | -0.17 Increased by +17.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 3.66 M Decreased by -23.55% | -27.94 M Decreased by -18.82% | Decreased by -763.65% Decreased by -55.41% |
| Mar 31, 24 | 2.97 M Decreased by -33.85% | -40.93 M Decreased by -211.62% | Decreased by -1.38 K% Decreased by -371.10% |
| Dec 31, 23 | 4.53 M Decreased by -15.47% | -27.45 M Decreased by -360.03% | Decreased by -605.83% Decreased by -444.20% |
| Sep 30, 23 | 3.68 M Increased by +16.21% | -15.79 M Decreased by -68.82% | Decreased by -429.31% Decreased by -45.28% |
| Jun 30, 23 | 4.79 M Increased by +22.15% | -23.52 M Decreased by -148.94% | Decreased by -491.37% Decreased by -103.79% |
| Mar 31, 23 | 4.49 M Increased by +28.67% | -13.13 M Increased by +17.62% | Decreased by -292.32% Increased by +35.97% |
| Dec 31, 22 | 5.36 M Increased by +66.72% | -5.97 M Increased by +48.40% | Decreased by -111.32% Increased by +69.05% |
| Sep 30, 22 | 3.17 M Decreased by -0.43% | -9.35 M Decreased by -28.46% | Decreased by -295.51% Decreased by -29.01% |